An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting.
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms InspirAda
- Sponsors Abbott Laboratories; AbbVie
- 01 Nov 2017 Results of subgroup analysis from Inspirada presented at the 25th United European Gastroenterology Week
- 09 May 2017 Results of effect of adalimumab on extraintestinal manifestation presented at the Digestive Disease Week 2017
- 09 May 2017 Results assessing the effect of adalimumab dose escalation on various outcomes among patients (n=129) with Ulcerative Colitis in clinical practice, presented at the Digestive Disease Week 2017.